Stockscreener 앱 받기
81.71
0.13%
-0.11
시간 외 거래:
82.14
0.43
+0.53%
Merck Co Inc 주식(MRK)의 최신 뉴스
Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com
Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 - The Motley Fool
Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com
Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus
Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha
Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com
FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com
FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus
Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com
Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus
RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com
Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha
Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs - Yahoo Finance
Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media
Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO
Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus
RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com
Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus
Merck: Phase 3 trial for dengue vaccine - marketscreener.com
Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha
Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus
Merck begins phase 3 trial of single-dose dengue vaccine - Investing.com Australia
Merck begins phase 3 trial of single-dose dengue vaccine By Investing.com - Investing.com Canada
Merck initiates phase 3 study for dengue vaccine in children By Investing.com - Investing.com Canada
Merck initiates phase 3 study for dengue vaccine in children - Investing.com
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate | MRK Stock News - GuruFocus
MRK Stock Quote Price and Forecast - CNN
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Business Wire
Here's Why Merck (MRK) Fell More Than Broader Market - Yahoo Finance
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials - MSN
Merck (MRK) Stock Declines 1.44%, Continuing Year-Long Downtrend - Daily Chhattisgarh News
Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA - Yahoo Finance
Unpacking the Latest Options Trading Trends in Merck & Co - Benzinga
Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty - BioWorld MedTech
ACIP Upheaval Leaves Merck & Co. In A Lurch - insights.citeline.com
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Merck Nixes Hopkins Patent on Keytruda Use in Win at Tribunal - Bloomberg Law News
Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty - BioWorld MedTech
Merck: Best Case For Option Collars We'll Ever See (NYSE:MRK) - Seeking Alpha
With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch - insights.citeline.com
Drug pricing reform talks with US government lack clarity, industry executives say - marketscreener.com
Merck Gets PTAB To Nix Johns Hopkins Cancer Drug Patent - Law360
Merck (NYSE:MRK) Gains FDA Approval For RSV Treatment, Reports Positive Trial Results - Yahoo Finance
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants - The Globe and Mail
Merck Secures FDA Nod For New RSV Antibody Enflonsia In Infants - Barchart.com
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE? - The Globe and Mail
Merck’s RSV drug approval and a drug manufacturer winds down - statnews.com
Cantor Fitzgerald maintains Neutral on Merck stock, target at $85 By Investing.com - Investing.com India
Merck (MRK) Gains FDA Approval for RSV Therapy Enflonsia - GuruFocus
US FDA approves Merck's RSV antibody for infants - Reuters
Merck wins FDA nod for RSV shot (MRK:NYSE) - Seeking Alpha
Merck: FDA approves Enflonsia RSV vaccine - marketscreener.com
1.09%
자본화:
|
볼륨(24시간):